TrialJournal of managed care & specialty pharmacy2020

The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.

Joshua A Roth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.